UBS Group’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-22,891
| Closed | -$641K | – | 11698 |
|
|
2022
Q1 | $641K | Sell |
22,891
-8,368
| -27% | -$229K | ﹤0.01% | 4501 |
|
|
2021
Q4 | $854K | Buy |
31,259
+17,936
| +135% | +$486K | ﹤0.01% | 4533 |
|
|
2021
Q3 | $363K | Sell |
13,323
-254,092
| -95% | -$6.28M | ﹤0.01% | 4926 |
|
|
2021
Q2 | $4.57M | Sell |
267,415
-93,156
| -26% | -$1.74M | ﹤0.01% | 2771 |
|
|
2021
Q1 | $7.53M | Sell |
360,571
-939,765
| -72% | -$21.7M | ﹤0.01% | 2204 |
|
|
2020
Q4 | $29.8M | Sell |
1,300,336
-113,281
| -8% | -$2.16M | 0.01% | 1095 |
|
|
2020
Q3 | $23.1M | Sell |
1,413,617
-777,994
| -35% | -$14.1M | 0.01% | 1084 |
|
|
2020
Q2 | $29.7M | Buy |
2,191,611
+3,199
| +0.1% | +$37.2K | 0.01% | 853 |
|
|
2020
Q1 | $25.9M | Buy |
2,188,412
+701,046
| +47% | +$15.5M | 0.01% | 850 |
|
|
2019
Q4 | $37M | Buy |
1,487,366
+97,386
| +7% | +$1.97M | 0.01% | 955 |
|
|
2019
Q3 | $23.6M | Buy |
1,389,980
+1,387,522
| +56,449% | +$25.3M | 0.01% | 1129 |
|
|
2019
Q2 | $56K | Buy |
2,458
+918
| +60% | +$24.8K | ﹤0.01% | 5825 |
|
|
2019
Q1 | $50K | Sell |
1,540
-13,156
| -90% | -$407K | ﹤0.01% | 5555 |
|
|
2018
Q4 | $415K | Buy |
14,696
+13,175
| +866% | +$386K | ﹤0.01% | 4411 |
|
|
2018
Q3 | $43K | Sell |
1,521
-6,513
| -81% | -$196K | ﹤0.01% | 6271 |
|
|
2018
Q2 | $301K | Buy |
8,034
+3,355
| +72% | +$132K | ﹤0.01% | 4686 |
|
|
2018
Q1 | $184K | Buy |
4,679
+2,096
| +81% | +$76.6K | ﹤0.01% | 4840 |
|
|
2017
Q4 | $84K | Sell |
2,583
-952
| -27% | -$28.5K | ﹤0.01% | 5481 |
|
|
2017
Q3 | $110K | Buy |
3,535
+1,289
| +57% | +$38.2K | ﹤0.01% | 5261 |
|
|
2017
Q2 | $63K | Sell |
2,246
-827
| -27% | -$18.7K | ﹤0.01% | 5497 |
|
|
2017
Q1 | $53K | Sell |
3,073
-2,874
| -48% | -$40.3K | ﹤0.01% | 5487 |
|
|
2016
Q4 | $72K | Buy |
5,947
+4,042
| +212% | +$52.3K | ﹤0.01% | 5543 |
|
|
2016
Q3 | $30K | Sell |
1,905
-1,432
| -43% | -$21.6K | ﹤0.01% | 5945 |
|
|
2016
Q2 | $44K | Buy |
3,337
+133
| +4% | +$2.08K | ﹤0.01% | 5615 |
|
|
2016
Q1 | $61K | Buy |
3,204
+1,616
| +102% | +$29.3K | ﹤0.01% | 5342 |
|
|
2015
Q4 | $35K | Buy |
1,588
+223
| +16% | +$4.41K | ﹤0.01% | 6190 |
|
|
2015
Q3 | $32K | Buy |
+1,365
| New | +$37.7K | ﹤0.01% | 6232 |
|
|
2015
Q1 | – | Sell |
-1,308
| Closed | -$24K | – | 9582 |
|
|
2014
Q4 | $24K | Buy |
+1,308
| New | +$23.5K | ﹤0.01% | 7406 |
|
UBS Group's XENT Position: Q2 2022 in Review
UBS Group sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 22,891 shares — an estimated $641K sold.
UBS Group first reported a position in XENT in Q4 2014 and held it in 28 quarters. The position peaked at $37M in Q4 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- UBS Group reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- UBS Group sold 22,891 Intersect ENT, Inc shares in Q2 2022, an estimated $641K.
- UBS Group first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 28 quarters.
- UBS Group's Intersect ENT, Inc position peaked at $37M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.